Nektar awarded $90 million in Lilly rezpeg dispute

28 September 2026

US biotech Nektar Therapeutics (Nasdaq: NKTR) has been awarded $90 million in damages after a federal jury found that US pharma major Eli Lilly (NYSE: LLY) breached the implied covenant of good faith and fair dealing in their agreement covering rezpegaldesleukin, known as rezpeg.

The September 24 verdict followed a trial that began on September 8 in the US District Court for the Northern District of California. Nektar disclosed the outcome in a Securities and Exchange Commission (SEC) filing signed September 25.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK